Jesduvroq (Daprodustat) Approved By US FDA For Anaemia Of Chronic Kidney Disease In Adults On Dialysis
February 02, 2023
February 02, 2023
LONDON, England, Feb. 2 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on Feb. 1, 2023:
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Jesduvroq is the fir . . .
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Jesduvroq is the fir . . .